OncoResponse, Inc.
2 clinical trials · Sponsor
| Record | Firm | Date |
|---|---|---|
| A Study of OR502, a Monoclonal Antibody Targeting LILRB2, Alone and in Combination With Anticancer Agents (NCT06090266) | OncoResponse, Inc. | 2023-10-24 |
| A Study of OR2805, a Monoclonal Antibody Targeting CD163, Alone and in Combination With Anticancer Agents (NCT05094804) | OncoResponse, Inc. | 2021-09-09 |
Track OncoResponse, Inc. automatically
Every clearance here is in the API, with alerts when new ones post.